EpiBone closed a convertible note funding round led by Kendall Capital Partners, with participation from LifeSpan Vision Ventures, EMV Capital and others. This additional funding will propel EpiBone’s ongoing pipeline development of products for skeletal reconstruction.
EpiBone’s technologies represent advanced treatment modalities that leverage autologous and allogeneic stem cells, 3D bioprinting and bioreactor technology to provide personalized, effective solutions for bone and osteochondral reconstruction.
In mid-2023, the company announced Investigational New Drug clearance from FDA to begin testing its lab-grown knee cartilage in humans. The treatment, an engineered allogenic osteochondral graft, has shown promise in preclinical studies and could benefit people with damaged knee cartilage caused by sports injuries, trauma or post-traumatic arthritis.
EpiBone closed a convertible note funding round led by Kendall Capital Partners, with participation from LifeSpan Vision Ventures, EMV Capital and others. This additional funding will propel EpiBone's ongoing pipeline development of products for skeletal reconstruction.
EpiBone closed a convertible note funding round led by Kendall Capital Partners, with participation from LifeSpan Vision Ventures, EMV Capital and others. This additional funding will propel EpiBone’s ongoing pipeline development of products for skeletal reconstruction.
EpiBone’s technologies represent advanced treatment modalities that leverage autologous and allogeneic stem cells, 3D bioprinting and bioreactor technology to provide personalized, effective solutions for bone and osteochondral reconstruction.
In mid-2023, the company announced Investigational New Drug clearance from FDA to begin testing its lab-grown knee cartilage in humans. The treatment, an engineered allogenic osteochondral graft, has shown promise in preclinical studies and could benefit people with damaged knee cartilage caused by sports injuries, trauma or post-traumatic arthritis.
Copy to clipboard 
